BIODESIX, INC. Capital Units, Cost to Investors
BIODESIX, INC. (BDSX) had Capital Units, Cost to Investors of $3.20 million as of 2020-12-31, per its 10-K filed 2022-03-14.
Discontinued › Notes › Equity
us-gaap:CapitalUnitsTotalCostToInvestors · last filed 2022-03-14
- 2020-12-31: Capital Units, Cost to Investors $3.20M.
| Period end | Capital Units, Cost to Investors |
|---|---|
| 2020-12-31 | $3.20M 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |